Consolidated Statements of Changes in Equity $ in Millions |
USD ($)
shares
|
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Cumulative Effect Adjustment To Equity
Amendments To IAS 37
USD ($)
|
[4] |
Issued capital [member]
USD ($)
shares
|
Issued capital [member]
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
shares
|
Share Premium
USD ($)
|
Share Premium
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Retained Earnings
USD ($)
|
Retained Earnings
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Retained Earnings
Cumulative Effect Adjustment To Equity
Amendments To IAS 37
USD ($)
|
[4] |
Other Reserves
USD ($)
|
Other Reserves
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Capital Redemption Reserve
USD ($)
|
Capital Redemption Reserve
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Cash Flow Hedge Reserve
USD ($)
|
Cash Flow Hedge Reserve
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Other Components of Equity
USD ($)
|
Other Components of Equity
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Total equity attributable to equity holders of the company
USD ($)
|
Total equity attributable to equity holders of the company
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
Total equity attributable to equity holders of the company
Cumulative Effect Adjustment To Equity
Amendments To IAS 37
USD ($)
|
[4] |
Non-controlling interest
USD ($)
|
Non-controlling interest
Opening Balance After Adjustment Cumulative Effect at Date of Initial Application
Amendments To IAS 37
USD ($)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at Mar. 31, 2021 | $ 10,502 | $ 332 | $ 359 | $ 12,087 | $ 908 | $ 17 | $ 2 | $ (3,263) | $ 10,442 | $ 60 | |||||||||||||||||||||||||
| Balance, Shares at Mar. 31, 2021 | shares | [1] | 4,245,146,114 | |||||||||||||||||||||||||||||||||
| Changes in equity for the year | |||||||||||||||||||||||||||||||||||
| Net Profit | 2,968 | 2,963 | 2,963 | 5 | |||||||||||||||||||||||||||||||
| Remeasurement of the net defined benefit liability/asset, net* | [2] | (11) | (11) | (11) | |||||||||||||||||||||||||||||||
| Equity instruments through other comprehensive income, net* (Refer to Notes 2.2 and 2.18) | [2] | 12 | 12 | 12 | |||||||||||||||||||||||||||||||
| Fair value changes on investments, net* (Refer to Notes 2.2 and 2.18) | [2] | (6) | (6) | (6) | |||||||||||||||||||||||||||||||
| Fair value changes on derivatives designated as cash flow hedge, net* (Refer to Notes 2.3 and 2.18) | [2] | (1) | (1) | (1) | |||||||||||||||||||||||||||||||
| Exchange differences on translation of foreign operations | (320) | (320) | (320) | ||||||||||||||||||||||||||||||||
| Total comprehensive income | 2,642 | 2,963 | (1) | (325) | 2,637 | 5 | |||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to Note 2.17) | 2 | 2 | 2 | ||||||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to note 2.17), Shares | shares | [1] | 3,674,152 | |||||||||||||||||||||||||||||||||
| Buyback of equity shares (Refer to Note 2.15) | (1,499) | $ (4) | (86) | (1,409) | (1,499) | ||||||||||||||||||||||||||||||
| Buyback of equity shares (Refer to note 2.5 and 2.15), Shares | shares | [1] | (55,807,337) | |||||||||||||||||||||||||||||||||
| Transaction costs related to buyback* (Refer to Note 2.15) | [2] | (4) | (4) | (4) | |||||||||||||||||||||||||||||||
| Amount transferred to capital redemption reserve upon Buyback (Refer to Note 2.15) | (4) | 4 | |||||||||||||||||||||||||||||||||
| Transfer to other reserves | (408) | 408 | |||||||||||||||||||||||||||||||||
| Transfer from other reserves on utilization | 146 | (146) | |||||||||||||||||||||||||||||||||
| Employee stock compensation expense (Refer to Note 2.17) | 52 | 52 | 52 | ||||||||||||||||||||||||||||||||
| Income tax benefit arising on exercise of stock options | 10 | 10 | 10 | ||||||||||||||||||||||||||||||||
| Dividends paid to non-controlling interest of subsidiary | (12) | (12) | |||||||||||||||||||||||||||||||||
| Dividends (1) | [3] | (1,699) | (1,699) | (1,699) | |||||||||||||||||||||||||||||||
| Balance at Mar. 31, 2022 | 9,994 | $ 9,992 | $ (2) | $ 328 | $ 328 | 337 | $ 337 | 11,672 | $ 11,670 | $ (2) | 1,170 | $ 1,170 | 21 | $ 21 | 1 | $ 1 | (3,588) | $ (3,588) | 9,941 | $ 9,939 | $ (2) | 53 | $ 53 | ||||||||||||
| Balance, Shares at Mar. 31, 2022 | shares | [1] | 4,193,012,929 | 4,193,012,929 | ||||||||||||||||||||||||||||||||
| Changes in equity for the year | |||||||||||||||||||||||||||||||||||
| Net Profit | 2,983 | 2,981 | 2,981 | 2 | |||||||||||||||||||||||||||||||
| Remeasurement of the net defined benefit liability/asset, net* | [2] | 4 | 4 | 4 | |||||||||||||||||||||||||||||||
| Equity instruments through other comprehensive income, net* (Refer to Notes 2.2 and 2.18) | [2] | (3) | (3) | (3) | |||||||||||||||||||||||||||||||
| Fair value changes on investments, net* (Refer to Notes 2.2 and 2.18) | [2] | (30) | (30) | (30) | |||||||||||||||||||||||||||||||
| Fair value changes on derivatives designated as cash flow hedge, net* (Refer to Notes 2.3 and 2.18) | [2] | (1) | (1) | (1) | |||||||||||||||||||||||||||||||
| Exchange differences on translation of foreign operations | (697) | (697) | (697) | ||||||||||||||||||||||||||||||||
| Total comprehensive income | 2,256 | 2,981 | (1) | (726) | 2,254 | 2 | |||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to Note 2.17) | 4 | 4 | 4 | ||||||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to note 2.17), Shares | shares | [1] | 3,801,344 | |||||||||||||||||||||||||||||||||
| Buyback of equity shares (Refer to Note 2.15) | (1,394) | $ (3) | (41) | (1,350) | (1,394) | ||||||||||||||||||||||||||||||
| Buyback of equity shares (Refer to note 2.5 and 2.15), Shares | shares | [1] | (60,426,348) | |||||||||||||||||||||||||||||||||
| Transaction costs related to buyback* (Refer to Note 2.15) | [2] | (3) | (3) | (3) | |||||||||||||||||||||||||||||||
| Amount transferred to capital redemption reserve upon Buyback (Refer to Note 2.15) | (3) | 3 | |||||||||||||||||||||||||||||||||
| Transfer to other reserves | (380) | 380 | |||||||||||||||||||||||||||||||||
| Transfer from other reserves on utilization | 180 | (180) | |||||||||||||||||||||||||||||||||
| Employee stock compensation expense (Refer to Note 2.17) | 63 | 63 | 63 | ||||||||||||||||||||||||||||||||
| Income tax benefit arising on exercise of stock options | 6 | 6 | 6 | ||||||||||||||||||||||||||||||||
| Dividends paid to non-controlling interest of subsidiary | (3) | (3) | |||||||||||||||||||||||||||||||||
| Dividends (1) | [3] | (1,697) | (1,697) | (1,697) | |||||||||||||||||||||||||||||||
| Balance at Mar. 31, 2023 | $ 9,224 | $ 325 | 366 | 11,401 | 1,370 | 24 | (4,314) | 9,172 | 52 | ||||||||||||||||||||||||||
| Balance, Shares at Mar. 31, 2023 | shares | 4,136,387,925 | 4,136,387,925 | [1] | ||||||||||||||||||||||||||||||||
| Changes in equity for the year | |||||||||||||||||||||||||||||||||||
| Net Profit | $ 3,169 | 3,167 | 3,167 | 2 | |||||||||||||||||||||||||||||||
| Remeasurement of the net defined benefit liability/asset, net* | [2] | 15 | 15 | 15 | |||||||||||||||||||||||||||||||
| Equity instruments through other comprehensive income, net* (Refer to Notes 2.2 and 2.18) | [2] | 2 | 2 | 2 | |||||||||||||||||||||||||||||||
| Fair value changes on investments, net* (Refer to Notes 2.2 and 2.18) | [2] | 17 | 17 | 17 | |||||||||||||||||||||||||||||||
| Fair value changes on derivatives designated as cash flow hedge, net* (Refer to Notes 2.3 and 2.18) | [2] | 1 | 1 | 1 | |||||||||||||||||||||||||||||||
| Exchange differences on translation of foreign operations | (117) | (116) | (116) | (1) | |||||||||||||||||||||||||||||||
| Total comprehensive income | 3,087 | 3,167 | 1 | (82) | 3,086 | 1 | |||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to Note 2.17) | 1 | 1 | 1 | ||||||||||||||||||||||||||||||||
| Shares issued on exercise of employee stock options (Refer to note 2.17), Shares | shares | [1] | 3,562,710 | |||||||||||||||||||||||||||||||||
| Transferred on account of options not exercised | (19) | 19 | |||||||||||||||||||||||||||||||||
| Transfer to other reserves | (357) | 357 | |||||||||||||||||||||||||||||||||
| Transfer from other reserves on utilization | 104 | (104) | |||||||||||||||||||||||||||||||||
| Employee stock compensation expense (Refer to Note 2.17) | 77 | 77 | 77 | ||||||||||||||||||||||||||||||||
| Buyback of shares pertaining to non controlling interest of subsidiary | (2) | (2) | |||||||||||||||||||||||||||||||||
| Dividends paid to non-controlling interest of subsidiary | (5) | (5) | |||||||||||||||||||||||||||||||||
| Dividends (1) | [3] | (1,777) | (1,777) | (1,777) | |||||||||||||||||||||||||||||||
| Balance at Mar. 31, 2024 | $ 10,605 | $ 325 | $ 425 | $ 12,557 | $ 1,623 | $ 24 | $ 1 | $ (4,396) | $ 10,559 | $ 46 | |||||||||||||||||||||||||
| Balance, Shares at Mar. 31, 2024 | shares | 4,139,950,635 | 4,139,950,635 | [1] | ||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||